Heart clinical trials

If you're exploring additional treatment options for a heart condition, you may be interested in an HonorHealth heart clinical trial.

HonorHealth's clinical trials focus on medical devices and medications that can improve treatment of cardiovascular conditions, including:

• Atrial fibrillation.
• Ventricular tachycardia.
• Mitral regurgitation.
• Aortic stenosis.
• Coronary artery disease.
• Cardiomyopathy.
• Heart valve disease.

When you participate in a clinical trial, not only are you playing an active role in your own healthcare, you’re also gaining access to innovative investigational devices and drugs before they're available to the general public.

Your clinical trial care team will include:

• Your cardiologist and your clinical trial research physician.
• A dedicated research nurse with an extensive background in both research and clinical trials and in cardiovascular disease management.
  • Your nurse is with you at every step of your journey:
    • At your initial appointment.
    • At your side during any medical procedures.
    • Following up with you throughout the trial phase — typically a five-year period.
• A PhD-level pharmacist.

About cardiovascular research at HonorHealth

Since its launch more than 10 years ago, the HonorHealth Cardiovascular Research Program has been driven by a singular passion: to create additional — and groundbreaking — treatment options for patients with cardiovascular disease. In fact, HonorHealth's Cardiovascular Research program is considered a major contributor to the field. An international leader in heart disease research, the program has seen its research findings presented in peer-reviewed journals and at international meetings.

Making major scientific contributions to the treatment of cardiovascular disease, HonorHealth researchers have:

• Consulted regularly with pharmaceutical and medical device companies on the development of new technologies.
• Contributed to FDA approvals for several coronary devices, including a fully dissolving heart stent. In 2016, HonorHealth interventional cardiologist and researcher David Rizik, MD, performed the first FDA-approved procedure to implant this device.
• Participated as one of 25 international sites for a clinical study on alleviating mitral valve regurgitation. Left untreated, it can lead to heart failure and death. Led by Dr. Rizik, HonorHealth specialists conducted the first two mitral valve replacements in the Southwest in 2017.
• Performed clinical trials leading to FDA approvals for medications, including a new form of anticoagulants for patients at risk of developing blood clots.